IFNAR Inducer

ODN 1585 sodium is a potent inducer of IFN and TNFα production. ODN 1585 sodium is a potent stimulator of NK (natural killer) function. ODN 1585 sodium increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 sodium induces regression of established melanomas in mice. ODN 1585 sodium can confer complete protection against malaria in mice. ODN 1585 sodium can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 sodium can be used as a vaccine adjuvant.

ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant.

2’3’-c-di-AM(PS)2 (Rp,Rp) enantiomer ammonium salt (ADU-S100 enantiomer ammonium salt) is the less active enantiomer of 2’3’-c-di-AM(PS)2 (Rp,Rp). 2’3’-c-di-AM(PS)2 (Rp,Rp) is an activator of stimulator of interferon genes (STING).

Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research.

LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). LMP2A (426-434) can trigger an immune response in individuals expressing different HLA-A*02 subtypes (A*02:01, A*02:03, A*02:06 and A*02:07). LMP2A (426-434) can induce a strong IFN-γ secretion response, stimulating the production of a high proportion of CD8⁺ IFN-γ⁺ T cells. LMP2A (426-434) induces specific CTLs to effectively kill target cells expressing LMP2A. LMP2A (426-434) can be used to study EBV-related malignant tumors (such as Hodgkin's disease and nasopharyngeal carcinoma) .

G3-YSD is a cGAS agonist. G3-YSD directly interacts with cGAS to enhance its enzymatic activity, promote the conversion of ATP and GTP into cGAMP, and trigger STING-dependent IFN-α/β secretion. G3-YSD acts as a viral mimic to replace actual viral DNA. G3-YSD is applicable to research related to long COVID and type 1 human immunodeficiency virus infection.

TLR7/8 agonist 6 is a TLR7/8 agonist with EC₅₀s of 0.18 μM and 5.34 μM in TLR7 or TLR8 HEK-SEAP reporter cells, respectively. TLR7/8 agonist 6 potently stimulates production of TNFα, IFNγ, and IL-1β. TLR7/8 agonist 6 can be used for research on cancer and infectious diseases.

CP-20961 is an interferon inducer. CP-20961 is a potent synthetic non-immunogenic adjuvant that induces arthritis.

VISTA-IN-3 (Compound A4) is a potent VISTA small molecule inhibitor with a K_D value of 0.49 μM. VISTA-IN-3 can induce the release of IFN-γ cytokines. VISTA-IN-3 synergistically enhances anti-cancer activity with PD-L1 antibody.

ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3'.

ODN 6016 is a CpG-A oligonucleotides. ODN 6016 can induce IFN-α production, can be used for researching immune disorders including immunodeficiency caused by HIV-1. ODN 6016 sequence: T-sp-C-G-A-C-G-T-C-G-T-G-G-sp-G-sp-G-sp-G.

HSV-60mer sodium is a 60 bp double-stranded DNA oligonucleotide derived from the HSV-1 genome, and also an IFNβ inducer. HSV-60mer sodium colocalizes with endogenous cytoplasmic IFI16 in immune cells. HSV-60mer sodium activates the transcription factors IRF3 and NF-κB, induces the production of proinflammatory cytokines, and inhibits HSV-1 replication in immune cells. HSV-60mer sodium can be used in studies related to herpes simplex virus type 1 infection.

MPD-1 (Maleimide-KGDEVD-doxorubicin) is a peptide drug conjugate (PDC). MPD-1 releases Doxorubicin (HY-15142) via radiation-activated caspase-3 cleavage, triggering a cytotoxic amplification cascade at the tumor site. MPD-1 enhances CD8⁺ T cell tumor infiltration, and activates antigen-presenting cells. MPD-1 enables dual-trigger payload release, amplifies cytotoxicity via in situ feedback, and selectively delivers payload to tumor microenvironments via enhanced albumin metabolism and macropinocytosis. MPD-1 exhibits antitumor efficacy in mouse colorectal cancer models. MPD-1 can be used for the research of colorectal cancer.

FITC-labeled ODN 1585 (sodium) is a potent inducer of IFN and TNFα production. FITC-labeled ODN 1585 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

Enpp-1-IN-32 is an orally active, selective ENPP-1 inhibitor with an IC₅₀ of 9.5 nM. Enpp-1-IN-32 shows selectivity over ENPP2/ENPP3. Enpp-1-IN-32 blocks cGAMP hydrolysis, and activates the STING pathway. Enpp-1-IN-32 exhibits antitumor effects in syngeneic mouse models. Enpp-1-IN-32 can be used for the research of triple-negative breast carcinoma.

VB-85247 is a STING agonist. VB-85247 induces upregulation of inflammatory cytokines IFNα/β, TNFα, IL6, and CXCL10, as well as maturation and activation of dendritic cells by activating the STING pathway. VB-85247 can achieve regression of intrabladder tumors and can be used in bladder cancer research.

hSTING activator-1 (Compound 68) is a STING agonist. hSTING activator-1 can effectively activate multiple human STING variants (R232, H232, HAQ) with EC₅₀ values of 56 nM, 89 nM and 51 nM, respectively. hSTING activator-1 activates the type I interferon pathway by directly binding to STING protein and stabilizing its conformation, promoting downstream IRF3 phosphorylation and cytokine release. hSTING activator-1 inhibits fibrosarcoma tumor growth and has potential in cancer research.

c-(2'FdAMP-2'FdIMP) (Compound 52),a derivative of cAIMP (HY-134375), is a cyclic dinucleotide (CDN). c-(2'FdAMP-2'FdIMP) is a STING activator and significantly induce STING-dependent IRF and NF-κB pathway signaling. c-(2'FdAMP-2'FdIMP) can be used for STING-based immunotherapy, such as cancers and infectious diseases research.

TLC388 is a novel camptothecin analog with limited antitumor activity in metastatic NEC.

CP-28888 is an interferon inducer, more potent in mice, but is less active in man and devoid of antirhinovirus effects.